In this regard, the obese osteoarthritic individuals in our study assumed to have low levels of leptin might have a better response (reduced weight) to leptin therapy, compared with those with higher levels of leptin. Hence, OA could be indirectly targeted in individuals with low leptin levels by treating obesity which is its major risk factor [9]. This evidence concerns the gene LEP and obesity disorder.